ALOX5 and chronic myelogenous leukemia, BCR-ABL1 positive: Zileuton (5-LO inhibitor) impairs CML LSC development [37], but although the oncogenicity of ALOX5 in the mouse model seemed to be compelling, in CML patients it has a low expression and the use of a 5-LO inhibitor does not show particular consequences [38].